MADISON, Wis. (WIFR) - For 14 years, Treyson Wallace’s family searched for answers. Born in 2009, Treyson failed a newborn ...
On the very day Noa was diagnosed, an experimental gene therapy and clinical trial were posted to treat Canavan disease. Noa was only the third patient in the world to be dosed with the gene therapy, ...
Like most children, Morgan enjoys games, showing off her toys, and spending some time on her tablet. But sadly, unlike most ...
Rithvik wasn’t dealt an easy hand in life. His first symptom — a distended abdomen — was identified during his birth ...
Morgan is living life with an ultra-rare disease. Her mother, Kelly Kozole, says doctors diagnosed Morgan with beta-propeller ...
The last day of February is Rare Disease Day, and one Union County group wanted to shine a light on those living with rare ...
President Donald Trump is expected to sign an executive order designating English as the official language of the United ...
Rare Disease Day, observed on Feb. 28, brings attention to uncommon diseases affecting populations of 200,000 or fewer. In ...
Williams, who has performed the National Anthem at baseball stadiums as part of Boehringer Ingelheim’s Breathless campaign, ...
Eyewitness News joined a visit to the Viscardi Center in Albertson, with 5-year-old Eli Reich, his father Scott, and the team of extraordinary staff guiding him through kindergarten.
Eyewitness News joined a visit to the Viscardi Center in Albertson, with 5-year-old Eli Reich, his father Scott, and the team ...
About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.